BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 2, 2014
View Archived Issues
Development and characterization of an orally available antifibrotic drug to treat renal fibrosis
Read More
Clinical evaluation of the duration between HPIV3 vaccinations in infants
Read More
Researchers from Xention present a novel antiarrhythmic therapy candidate
Read More
Eli Lilly to begin phase I trial of LY-3009120 in patients with advanced cancer
Read More
BioCryst receives funding to advance candidate for Marburg virus disease
Read More
Peregrine Pharmaceuticals begins phase III trial of bavituximab
Read More
Heat Biologics opens enrollment in phase I/II study of HS-410
Read More
Phase I study of AMP-514 begins for advanced solid malignancies
Read More
Coagulation factor VIII deficiency as a risk factor for decreased skeletal health
Read More
Janssen R&D Ireland discloses new antiviral agents
Read More
Pfizer patents novel kynurenine aminotransferase II inhibitors
Read More
Lilly patent reports new JAK inhibitors for cancer
Read More
New mitochondrial F1F0-ATPase inhibitors designed by Lycera Corp.
Read More
Bayer presents preliminary results from a phase II trial of copanlisib in lymphoma
Read More
Scientists at Glenmark Pharmaceuticals disclose novel MPGES-1 inhibitors
Read More
FDA removes partial clinical hold on Cell Therapeutics' tosedostat
Read More
Pfizer files for approval of bosutinib in Japan
Read More
RFS Pharma presents novel DAPN phosphoramidate prodrugs with promising activity against HCV
Read More
NICE publishes final draft guidance recommending aflibercept for macular edema
Read More
NICE final draft guidance recommends funding of pixantrone
Read More
NICE issues new draft guidance recommending Firmagon for prostate cancer
Read More
PanOptica to study PAN-90806 in patients with wet AMD
Read More
NINDS investigates SGS-742 in phase II trial for SSADH deficiency
Read More